Anti-Fibroblast activation protein, alpha antibody

• WB

Unknown

Western blot - Anti-Fibroblast activation protein, alpha antibody (AB28244)

All lanes:

Western blot - Anti-Fibroblast activation protein, alpha antibody (ab28244) at 1/1000 dilution

Lane 1:

Recombinant Human FAPalpha at 0.08 µg

Lane 2:

Recombinant Human FAPalpha at 0.04 µg

Lane 3:

Recombinant Human FAPalpha at 0.02 µg

Lane 4:

Recombinant Human FAPalpha at 0.01 µg

Lane 5:

Recombinant Human FAPalpha at 0.005 µg

Predicted band size: 88 kDa

false

• WB

CiteAb

Western blot - Anti-Fibroblast activation protein, alpha antibody (AB28244)

Fibroblast activation protein western blotting using Anti-Fibroblast activation protein, alpha antibody ab28244. Publication image and figure legend from Wei, L., Ye, H., et al., 2018, Cell Death Dis, PubMed 30337520.

Characterization of primary NAFs and CAFsa The expression of α-SMA in tumor stroma was assayed by immunohistochemical staining, indicating that CAFs were abundant in pancreatic tumor stroma. b The morphological images of NAFs and CAFs. c Immunofluorescence staining showed the subcellular localization and the expression of α-SMA and FAP in NAFs and CAFs. Scale bar = 50 μm, magnification, x400. d The mRNA expression levels of α-SMA, FAP, and FSP1 in NAFs and CAFs (passage 4) isolated from three patients were detected by qRT-PCR analysis. n = 3 (replicating from three patients), ***p < < 0.001. e Western blot analysis shows the expression of α-SMA and FAP in NAFs and CAFs derived from four pairs of non-neoplastic pancreatic tissues and tumor tissues. f, g qRT-PCR and western blot analysis show the different expression levels of α-SMA and FAP in CAFs at different passages. Compared with the fourth-passage CAFs (CAFs-P4), the expression of α-SMA and FAP in CAFs-P8 had no significant difference, but the expression in CAFs-P12 significantly decreased. n = 3 (replicating from three patients), ns : not significantly different, *p < < 0.05

false

• WB

CiteAb

Western blot - Anti-Fibroblast activation protein, alpha antibody (AB28244)

Fibroblast activation protein western blotting using Anti-Fibroblast activation protein, alpha antibody ab28244. Publication image and figure legend from Kato, R., Haratani, K., et al., 2021, Br J Cancer, PubMed 33299131.

Nintedanib inhibits both the proliferation and activation of fibroblasts.a Cell viability assay for nintedanib and either NIH-3T3 cells treated with TGF-β1, H1703 cells (positive control) or B16-F10 cells (negative control). Data are means ± SEM for two independent experiments, each performed with six technical replicates. b Cell proliferation assay for nintedanib and TGF-β1-stimulated NIH-3T3 cells. The cells were treated with 0.5 or 1 μm nintedanib for 24, 48 or 72 h, after which living cells were counted by flow cytometry and normalised by those in untreated samples. Data are means + SEM for two independent experiments, each performed with two technical replicates. P values were determined by one-way ANOVA with Tukey's correction for multiple comparisons and are shown only if <0.05. c Immunoblot analysis of FAP and β-actin (loading control) (left) as well as densitometric quantification of the FAP/β-actin ratio (right) for NIH-3T3 cells stimulated with TGF-β1 and exposed to the indicated concentrations of nintedanib. The quantitative data are means + SEM for two independent experiments. P values were determined by one-way ANOVA with Tukey's correction for multiple comparisons. d Immunoblot analysis of FAP and β-actin in lysates of cultured B16-F10 cells, B16-F10 tumour tissue, and normal mouse skin tissue (positive control). e Flow cytometric analysis of FAP+ cells in B16-F10 tumours derived from mice treated with vehicle or nintedanib for 7 days. Data are expressed as number of FAP+ cells per milligram of wet tumour weight and are means ± SEM for six mice per group. The P value was determined with the unpaired t-test. f Representative immunohistochemical staining of α-SMA and Sirius red staining of collagen (left) as well as the corresponding percentage positive areas (right) for B16-F10 tumours derived from mice treated with vehicle or nintedanib for 7 days. Scale bars, 100 μm. The quantitative data are means ± SEM for five or six mice per group. The P values were determined with the unpaired t-test. g Immunoblot analysis of FAP and β-actin (left) as well as densitometric quantification of the FAP/β-actin ratio for lysates of B16-F10 tumour tissue derived from mice treated with vehicle or nintedanib for 7 days. The quantitative data are means ± SEM for five mice per group. The P value was determined with the unpaired t-test.

false

• WB

CiteAb

Western blot - Anti-Fibroblast activation protein, alpha antibody (AB28244)

Fibroblast activation protein western blotting using Anti-Fibroblast activation protein, alpha antibody ab28244. Publication image and figure legend from Kato, R., Haratani, K., et al., 2021, Br J Cancer, Pubmed 33299131.

Nintedanib inhibits both the proliferation and activation of fibroblasts.a Cell viability assay for nintedanib and either NIH-3T3 cells treated with TGF-β1, H1703 cells (positive control) or B16-F10 cells (negative control). Data are means ± SEM for two independent experiments, each performed with six technical replicates. b Cell proliferation assay for nintedanib and TGF-β1-stimulated NIH-3T3 cells. The cells were treated with 0.5 or 1 μm nintedanib for 24, 48 or 72 h, after which living cells were counted by flow cytometry and normalised by those in untreated samples. Data are means + SEM for two independent experiments, each performed with two technical replicates. P values were determined by one-way ANOVA with Tukey's correction for multiple comparisons and are shown only if <0.05. c Immunoblot analysis of FAP and β-actin (loading control) (left) as well as densitometric quantification of the FAP/β-actin ratio (right) for NIH-3T3 cells stimulated with TGF-β1 and exposed to the indicated concentrations of nintedanib. The quantitative data are means + SEM for two independent experiments. P values were determined by one-way ANOVA with Tukey's correction for multiple comparisons. d Immunoblot analysis of FAP and β-actin in lysates of cultured B16-F10 cells, B16-F10 tumour tissue, and normal mouse skin tissue (positive control). e Flow cytometric analysis of FAP+ cells in B16-F10 tumours derived from mice treated with vehicle or nintedanib for 7 days. Data are expressed as number of FAP+ cells per milligram of wet tumour weight and are means ± SEM for six mice per group. The P value was determined with the unpaired t-test. f Representative immunohistochemical staining of α-SMA and Sirius red staining of collagen (left) as well as the corresponding percentage positive areas (right) for B16-F10 tumours derived from mice treated with vehicle or nintedanib for 7 days. Scale bars, 100 μm. The quantitative data are means ± SEM for five or six mice per group. The P values were determined with the unpaired t-test. g Immunoblot analysis of FAP and β-actin (left) as well as densitometric quantification of the FAP/β-actin ratio for lysates of B16-F10 tumour tissue derived from mice treated with vehicle or nintedanib for 7 days. The quantitative data are means ± SEM for five mice per group. The P value was determined with the unpaired t-test.

false